Advertisement
Study results from ASH 2019 shed light on treatment
Targeting pyrimidine synthesis inhibits GSC self-renewal and tumorigenesis
Study affirms XRT’s utility
Relapse more likely with faster PSA doubling time
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Two-year follow-up confirms initial findings of the INO-VATE trial
Results prompt clinical practice change
Cleveland Clinic-led research employs advanced image analysis to inform dose delivery
Dr. Eng and colleagues will probe role of microbial/immune system interactions in cancer progression
Cleveland Clinic study finds it’s safe and effective
Enroll patients now in KEYNOTE-630 trial
Advertisement
Advertisement